Price point is an entry barrier in sports nutrition for a large set of consumers
Tirupati manufactures renowned brands, including Optimum Nutrition, PediaSure, Centrum, Endura Mass, Montair LC, Azee, Softovac, and others
Kotak Alternate Asset Managers Limited (Kotak Alts) announced an investment of Rs 1,050 Crore in Tirupati Medicare Limited (Tirupati). This investment will facilitate a complete exit for the existing investor and support Tirupati’s expansion plans.
Founded in 2005, Tirupati is a leading player in the nutraceutical, pharmaceutical, and Ayush contract development and manufacturing sectors in India. The company boasts long-standing relationships with global industry leaders such as Herbalife, Glanbia, Abbott, Haleon, Cipla, Dr. Reddy’s, Torrent, Macleods, Pfizer, Lupin, Dabur, and others. Tirupati manufactures renowned brands, including Optimum Nutrition, PediaSure, Centrum, Endura Mass, Montair LC, Azee, Softovac, and others. It holds the distinction of having the largest installed capacity for oral solids and powders among Indian nutraceutical contract manufacturers.
Eshwar Karra, Managing Partner at Kotak Alts, said, “We are excited to partner with Tirupati, the largest player in the Indian nutraceutical contract manufacturing space. With its marquee customer base and extensive manufacturing capabilities across various dosage forms, Tirupati is well-positioned to capitalize on the growth opportunities in the Indian nutraceutical market.”
Rahul Shah, Partner at Kotak Alts, stated, “Our investment in Tirupati, a leading nutraceutical CDMO, comes at a pivotal moment as the company is poised for substantial growth in the domestic market and plans to foray into exports. We are delighted to support Tirupati’s expansion plans and assist the company in preparing for its journey towards an IPO.”